NCT06651281
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
At risk: Primary endpoint(s) modified, primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 29 versions: 27 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria shortened, about 5 words
- Notable Primary endpoint(s) modified
- Primary endpoint(s) modified
- Notable Primary endpoints: 2 to 4
- Secondary endpoints shortened, about 63 words
- Notable Eligibility criteria expanded, about 8 words
- Secondary endpoints: details revised at 4 of 4 entries
- Site details revised at 3 of 37 sites
- Minor Site contacts updated at 1 of 37 sitesv25
Show 21 earlier versionsHide 21 earlier versions
- Minor Study sites revised (37)v24
- Minor Site details revised at 1 of 37 sitesv23
- Minor Site contacts updated at 1 of 37 sitesv22
- Minor Site contacts updated at 2 of 37 sitesv21
- Minor Study sites: 38 to 37v20
- Minor Site contacts updated at 3 of 38 sitesv19
- Minor Study sites: 37 to 38v18
- Minor Study sites: 34 to 37v17
- Minor Study sites: 21 to 34v16
- Minor Study sites: 15 to 21v15
- Minor Study sites: 13 to 15v14
- Minor Study sites: 11 to 13v13
- Minor Study sites: 10 to 11v12
- Minor Study sites: 8 to 10v11
- Minor Study sites: 4 to 8v10
- Minor Study sites: 3 to 4v9
- Minor Study sites: 2 to 3v8
- Minor Enrollment target: 1349 to 1380
- Study sites: 1 to 2
- Minor Start date changed from estimate of Dec 18, 2024 to Nov 25, 2024v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Minor Secondary endpoints: details revised at 1 of 4 entriesv3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 378 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 364 weeks
Arms and interventions
Group 1: Low Dose UnblindedExperimental
Participants receive a low dose subcutaneous (SC) tulisokibart regimen.
Group 2: High Dose UnblindedExperimental
Participants receive a high dose SC tulisokibart regimen.
Group 3: High Dose BlindedExperimental
Participants receive a blinded high dose SC tulisokibart regimen.
Group 4: Low Dose BlindedExperimental
Participants receive a blinded low dose SC tulisokibart regimen.
Drugs: Tulisokibart, Placebo to tulisokibart
Sites
37 sites in 7 countries
Poland 14, United States 12, France 4, Czechia 2, Hungary 2, United Kingdom 2, Georgia 1